Hydrochlorothiazide/metoprolol succinate - AstraZeneca

Drug Profile

Hydrochlorothiazide/metoprolol succinate - AstraZeneca

Alternative Names: DUTOPROL

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antihypertensives; Benzothiadiazines
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 28 Feb 2014 Covis enters into an asset purchase agreement with AstrZeneca for acquiring hydrochlorothiazide/metoprolol succinate (Covis Form 51-102F4, July 2015)
  • 12 Apr 2012 Launched for Hypertension in USA (PO)
  • 28 Aug 2006 Registered for Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top